间叶型胃癌调控增强子图谱揭示亚型特异性表观基因组景观与可靶向脆弱性
研究分析约1000例原发胃癌和细胞系的转录组,构建并验证了993基因的间叶型胃癌分类器,并在超过1200例患者中分析临床与基因组关联。对49例原发胃癌和细胞系进行全基因组表观基因组分析,揭示间叶型胃癌独特增强子景观,TEAD1为其主调控因子,NUAK1为下游靶点,NUAK1抑制与顺铂联用具协同效应。
要点
- 993基因间叶型胃癌分类器适用于回顾性队列或前瞻性单样本。
- 间叶型胃癌与不良生存、治疗抵抗及可靶向基因组改变少相关。
- TEAD1为间叶型胃癌增强子主调控因子,药理学抑制显示优先敏感性。
核心结论
- 间叶型胃癌具有独特表观基因组景观,TEAD1抑制和NUAK1抑制联合顺铂可能为潜在可靶向选择。
研究设计与样本
- 分析约1000例原发胃癌和细胞系转录组以构建共识间叶型胃癌分类器,并在超过1200例胃癌患者中分析临床与基因组关联。
- 生成49例原发胃癌和胃癌细胞系的全基因组表观基因组图谱(H3K27ac、H3K4me1和ATAC-seq)以识别间叶型胃癌特异性增强子景观。
主要发现
- 间叶型胃癌多队列分析证实与不良生存、治疗抵抗及可靶向基因组改变少相关。
- 增强子图谱分析揭示间叶型胃癌独特表观基因组景观,TEAD1为间叶型胃癌增强子主调控因子。
- 间叶型胃癌对TEAD1药理学抑制表现出优先敏感性。
- 间叶型胃癌超级增强子分析突出NUAK1激酶为下游靶点,NUAK1抑制与顺铂治疗间观察到协同效应。
关键数值与推荐
- 识别并验证993基因的癌细胞内在间叶型胃癌分类器,适用于回顾性队列或前瞻性单样本。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Gastric cancer (GC) comprises multiple molecular subtypes. Recent studies have highlighted mesenchymal-subtype GC (Mes-GC) as a clinically aggressive subtype with few treatment options. Combining multiple studies, we derived and applied a consensus Mes-GC classifier to define the Mes-GC enhancer landscape revealing disease vulnerabilities. DESIGN: Transcriptomic profiles of ~1000 primary GCs and cell lines were analysed to derive a consensus Mes-GC classifier. Clinical and genomic associations were performed across >1200 patients with GC. Genome-wide epigenomic profiles (H3K27ac, H3K4me1 and assay for transposase-accessible chromatin with sequencing (ATAC-seq)) of 49 primary GCs and GC cell lines were generated to identify Mes-GC-specific enhancer landscapes. Upstream regulators and downstream targets of Mes-GC enhancers were interrogated using chromatin immunoprecipitation followed by sequencing (ChIP-seq), RNA sequencing, CRISPR/Cas9 editing, functional assays and pharmacological inhibition. RESULTS: We identified and validated a 993-gene cancer-cell intrinsic Mes-GC classifier applicable to retrospective cohorts or prospective single samples. Multicohort analysis of Mes-GCs confirmed associations with poor patient survival, therapy resistance and few targetable genomic alterations. Analysis of enhancer profiles revealed a distinctive Mes-GC epigenomic landscape, with TEAD1 as a master regulator of Mes-GC enhancers and Mes-GCs exhibiting preferential sensitivity to TEAD1 pharmacological inhibition. Analysis of Mes-GC super-enhancers also highlighted NUAK1 kinase as a downstream target, with synergistic effects observed between NUAK1 inhibition and cisplatin treatment. CONCLUSION: Our results establish a consensus Mes-GC classifier applicable to multiple transcriptomic scenarios. Mes-GCs exhibit a distinct epigenomic landscape, and TEAD1 inhibition and combinatorial NUAK1 inhibition/cisplatin may represent potential targetable options.
引用
- Ho SWT, Sheng T, Xing M, et al. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut. 2022. PMID: 35817555. doi:10.1136/gutjnl-2021-326483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。